NIH to Ban Deals With Drug Firms

WASHINGTON — Under a far-reaching reform to be announced today, all staff scientists at the National Institutes of Health will be banned from accepting any consulting fees or other income from drug companies, and the employees must also divest industry stock holdings, officials said.

By David Willman

February 1, 2005